Inhibikase Therapeutics Inc expected to post a loss of 17  cents a share - Earnings Preview

Inhibikase Therapeutics

29/03/2022 22:37

* Inhibikase Therapeutics Inc  IKT.OQ   IKT.O  is expected
to report results on March 31.
    * The Atlanta Georgia-based  company is expected to report
revenue
of $300 thousand, according to the estimate from one analyst,
based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Inhibikase
Therapeutics
Inc is for a loss of 17 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $10.5​, above​ its last closing price
of $1.35. ​​​

This summary was machine generated March 29 at 21:37 GMT.  All
figures in US dollars  unless otherwise stated